Diskussionsleiter: A. Abdin (Lübeck), B. Pieske (Berlin)
| (P1713) | Essential myosin light chain phosphorylation as novel therapeutic target in heart failure and dilated cardiomyopathy | |
| M. Müller, J.-N. Boeckel, K. S. Frese, J. Haas, C. Scheiner, O. F. Tugrul, E. Kayvanpour, H. A. Katus, B. Meder (Heidelberg) | ||
| (P1714) | Stem Cell therapy in IscEmic Non-treatable Cardiac diseasE (SCIENCE). A prospective randomized, multicenter, placebo-controlled, double-blind, investigator-initiated trial |
|
| C. Paitazoglou, M. W. Bergmann, K.-H. Kuck, A. Metzner, B. Vrtovec, S. A. Chamuleau, W. Wojakowski, M. Gyöngyösi, J. Kastrup, für die Studiengruppe: SCIENCE (Hamburg; Ljubljana, SI; Utrecht, NL; Katowice, PL; Wien, AT; København, DK) | ||
| (P1715) | Off-label Rapamycin as an individualized therapeutic approach for dilated cardiomyopathy caused by a lamin A/C mutation | |
| B. Neupane, Q. Zhou, C. Maleck, M. Gawaz, M. Gramlich (Tübingen) | ||
| (P1716) | Impact of positive airway pressure therapy on cardiac function in patients with heart failure with reduced ejection fraction and obstructive sleep apnea – a randomized, controlled trial | |
| T. Bitter, K. Mohemed, H. Fox, B. Wellmann, D. Horstkotte, O. Oldenburg, für die Studiengruppe: APAP (Bad Oeynhausen) | ||
| (P1717) | Influence of Ivabradine on levels of novel cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure | |
| P. Jirak, D. Fejzic, V. Paar, B. Wernly, R. Pistulli, I. Rohm, C. Jung, U. C. Hoppe, P. C. Schulze, A. Yilmaz, M. Lichtenauer, D. Kretzschmar (Salzburg, AT; Jena, Düsseldorf, Schmalkalden) | ||
| (P1718) | Insight from a first German retrospective multicenter analysis of eCPR patients: The Lazarus register | |
| S. Kriechbaum, T. Spangenberg, J. Reifart, A. Dreher, J. S. Wolter, J. Schewel, A. Rolf, F. Meincke, E. Bahlmann, H. Van der Schalk, K.-H. Kuck, C. Hamm, C. Liebetrau, A. Ghanem (Bad Nauheim, Hamburg) |